据港交所6月20日披露,CLOUDBREAK PHARMA INC.(下称:拨康视云)通过港交所上市聆讯,建银国际、华泰国际为其联席保荐人。招股书披露,拨康视云是一间临床阶段眼科生物科技公司,致力于开发各种疗法。公司拥有两款核心产品(CBT-001及CBT-009),均为自主开发。CBT-001适用于治疗翼状胬肉(一种良性增生性眼表疾病),分别于2022年6月及2023年9月在美国及中国启动第3...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.